At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Systane iLux Treatmentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of the Systane iLux System on Preoperative Cataract Patients on Dry Eye Disease Due to Meibomian Gland Dysfunction
In Brief
A clinical study evaluating Systane iLux Treatment for Dry Eye Disease and 3 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20252026
Enrollment StartJun 2024
First PostedJul 2024
Primary CompletionFeb 2025
TodayJul 2026
First PostedJul 3, 2024
Enrollment StartJun 3, 2024
Primary CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.0 years ago
Interventions
Systane iLux Treatmentdevice
The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.